94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Public Health
Sec. Health Economics
Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1401930
Cost-Effectiveness analysis of herpes-zoster vaccination for adults aged 50 years in Zhejiang province, China
Provisionally accepted- Zhejiang Center for Disease Control and Prevention (Zhejiang CDC), Hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Live-attenuated zoster vaccine (LZV) and adjuvanted recombinant zoster vaccine (RZV) have been licensed in China. This study aimed to evaluateassess and compare the cost-effectiveness of two herpes-zoster (HZ) vaccination strategies in the birth cohort of 50 years age.The cost-effectiveness of RZV and LZV was compared with to no HZ vaccination through using the lifetime Markov model from a societal perspective. Model parameters were derived obtained from up-to-date published literatures or and statistical data up to date. The cost of vaccination and medical treatment, quality adjusted life years (QALYs), number of herpes-zoster and related complication cases averted, and incremental cost-effectiveness ratio (ICER) were calculated. We conducted sSensitivity analyses were performed to assess the robustness of the findingsresults.: Compared to no-vaccination, the RZV vaccination strategy would preventavert 4126 HZ cases, 772 PHN cases, whileand the LZV vaccination strategy would avert 2355 HZ cases, 467 PHN cases. The ICERs were estimated at 711.46 US $/QALY, 914.62 US $/QALY for RZV vaccination and LZV vaccination, respectively.Conclusions: HZ vaccination strategy could enhanceincrease health benefits at a substantial cost. RZV vaccination was predicted to be more cost-effective than the LZV.
Keywords: Cost-Effectiveness, Herpes-zoster, adjuvanted recombinant zoster vaccine, Liveattenuated zoster vaccine, Vaccination
Received: 16 Mar 2024; Accepted: 17 Apr 2025.
Copyright: © 2025 Chen, Ding and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yu Hu, Zhejiang Center for Disease Control and Prevention (Zhejiang CDC), Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.